Assay Development and Adaptation (AD/A) Core
AD/A biologists develop NIH target assays for multiplex HT flow cytometry. AD/A assembles expertise in cell and molecular biology and biochemistry with the scientific leaders, Sklar and Prossnitz, providing extensive experience in biological applications of flow cytometry.
AD/A partners to develop assays that arise as part of outreach efforts, allowing partner investigators to demonstrate assay proof of principle for X01 and R03 submissions. AD/A is responsible for optimizing assays that come into the Center via X01, R03, and R21 mechanisms that have not been previously sponsored through outreach by our Center.
AD/A prototypes secondary assays for individual investigators as well as for MLPCN Centers wishing to evaluate specificity and selectivity, such as in multiplex assays and counter-screens, as time and resources permit.
Innovation:: AD/A will identify consortia of investigators through outreach to develop multiplex target families of GTPases and kinases for discovery of probes for protein-protein and protein-small molecular interaction.